SGLT-2 & DPP-4 Inhibitors, Conquering the Realm of Diabetes

  • Posted by: SI-Insights
  • Jan 1, 2020

Gliptins and gliflozin are all over the place, creating a buzz in the Indian Pharma Market. While many manufacturers have launched the drug, many more are in the queue for getting started in 2021.

Interesting strategies are being implemented to cater the market by both domestic and multinational pharmaceuticals, be it co-marketing or co-promotion with the same or different brand names.

  • When the same drugs with different combinations are sold by multiple players and similar (MoA) drugs are available widely.
  • When everyone is trying to maximize the reach and increase their share.

It is interesting to know what’s working for one and not for others, how one is winning the hearts of physicians while others are lagging behind. These are the obvious question that strikes and not only that; these questions lead to further introspections and an urge to know more amplify.

To give the rest to your curiosity and provide a series of in-depth answers to all your questions. We are in the process of completing our brand new;SGLT-2 study where we are catering to all the brands in greater detail.

It’s time to make a difference in the market place as everyone is running to stabilized their brand equity in the high growth segment.

You can be a part of that as well.

Reach us for more details or call +91 7506221809